• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: VERYAN MEDICAL LTD BIOMIMICS 3D VASCULAR STENT SYSTEM

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

VERYAN MEDICAL LTD BIOMIMICS 3D VASCULAR STENT SYSTEM Back to Search Results
Model Number 142122-03
Medical Device Problem Code Adverse Event Without Identified Device or Use Problem (2993)
Health Effect - Clinical Codes Pain (1994); Restenosis (4576)
Date of Event 12/20/2022
Type of Reportable Event Serious Injury
Additional Manufacturer Narrative
There was no reported device malfunction and the device was not returned for analysis.A review has been performed of the manufacturing certificate of conformance associated with this lot.There were no non-conformances or deviations which could be associated with this event.Based on the case information and related record review, a conclusive cause for the reported patient effects, and the relationship to the product, if any, cannot be determined.The reported patient effects of restenosis leading to intervention and claudication/leg pain are listed in the biomimics 3d instructions for use and are known patient effects of peripheral stenting procedures.There is no indication of a product quality issue with respect to the design, manufacture or labelling of the device.If further information regarding this event becomes available, a follow-up report will be submitted.
 
Event or Problem Description
The patient was treated as part of the mimics 3d usa post-market observational study.On the (b)(6) 2021, the patient was implanted with one 7.0 x 60mm biomimics 3d (bm3d) stent to treat a denovo lesion of the superficial femoral artery (sfa) middle third to sfa distal third segment in the left leg.An antegrade approach was used and the lesion was prepared using atherectomy and pre-dilated with percutaneous transluminal angioplasty (pta).The treated segment was post-dilated with pta.The site reported that on (b)(6) 2023, a restenosis of treated segment (target lesion) was identified.It was reported as not related to the device and not related to the procedure but due to a worsening of the pre-existing condition.It was reported as target lesion related.The patient attended clinic with left leg extremity (lle) claudication.The left sfa to the popliteal segment was treated with angioplasty and laser atherectomy.The patient outcome was reported as resolved/recovered and the device remains implanted.The event was reviewed by veryan on (b)(6) 2023 and considered possibly related to the device.
 
Additional Manufacturer Narrative
There was no reported device malfunction and the device was not returned for analysis.A review has been performed of the manufacturing certificate of conformance associated with this lot.There were no non-conformances or deviations which could be associated with this event.Based on the case information and related record review, a conclusive cause for the reported patient effects, and the relationship to the product, if any, cannot be determined.The reported patient effects of restenosis leading to intervention and claudication/leg pain are listed in the biomimics 3d instructions for use and are known patient effects of peripheral stenting procedures.There is no indication of a product quality issue with respect to the design, manufacture or labelling of the device.If further information regarding this event becomes available, a follow-up report will be submitted.Section b.3.Was updated to reflect the date of onset 20-dec-22, section b.5.Was updated to reflect the date of onset, the distal target lesion segment update and the contralateral approach used, section d.3.And g.1 were updated to reflect veryan's address, and sections g.6.And h.2.Were updated to reflect the report type (follow-up 01) and reason and section h.11.Was updated to reflect the sections of this report that were updated.
 
Event or Problem Description
The patient was treated as part of the mimics 3d usa post-market observational study.On the (b)(6) 2021, the patient was implanted with one 7.0 x 60mm biomimics 3d (bm3d) stent to treat a denovo lesion of the superficial femoral artery (sfa) middle third segment in the left leg.A contralateral approach was used and the lesion was prepared using atherectomy and pre-dilated with percutaneous transluminal angioplasty (pta).The treated segment was post-dilated with pta.The site reported that on (b)(6) 2022, a restenosis of treated segment (target lesion) was identified.It was reported as not related to the device and not related to the procedure but due to a worsening of the pre-existing condition.It was reported as target lesion-related.The patient attended clinic with left leg extremity (lle) claudication.The left sfa to the popliteal segment was treated with angioplasty and laser atherectomy.The patient outcome was reported as resolved/recovered and the device remains implanted.The event was reviewed by veryan on (b)(6) 2023 and considered possibly related to the device.Additional information was provided by the site on (b)(6) 2024 where the date of onset and the distal segment of the target lesion as well as the approach used at the index procedure were updated.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
BIOMIMICS 3D VASCULAR STENT SYSTEM
Common Device Name
BIOMIMICS 3D VASCULAR STENT SYSTEM
Manufacturer (Section D)
VERYAN MEDICAL LTD
block 5
parkmore east business park
galway, H91 V 0TX
EI  H91 V0TX
Manufacturer Contact
alan mcdonagh
block 5
parkmore east business park
galway, H91 V-0TX
EI   H91 V0TX
MDR Report Key16404316
Report Number3011632150-2023-00021
Device Sequence Number3365018
Product Code NIP
UDI-Device Identifier05391526850404
UDI-Public(01)05391526850404(17)220523(11)201022(10)0000056142
Combination Product (Y/N)N
Initial Reporter StateFL
Initial Reporter CountryUS
PMA/510(K) Number
P180003
Number of Events Summarized1
Summary Report (Y/N)N
Device Implanted Year2021
Serviced by Third Party (Y/N)Unknown
Reporter Type Manufacturer
Report Source Study,Health Professional
Initial Reporter Occupation Physician
Type of Report Initial,Followup
Report Date (Section B) 03/26/2024
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Operator of Device Health Professional
Device Expiration Date05/23/2022
Device Model Number142122-03
Device Catalogue Number142122-03
Device Lot Number0000056142
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Type of Report(Section G)Thirty-Day
Initial Date Received by Manufacturer 01/23/2023
Supplement Date Received by Manufacturer03/01/2024
Initial Report FDA Received Date02/20/2023
Supplement Report FDA Received Date03/26/2024
Was Device Evaluated by Manufacturer? (Y/N) Device Not Returned to Manufacturer
Date Device Manufactured10/22/2020
Is the Device Labeled for Single Use? (Y/N) Yes
Is This a Single-Use Device that was
Reprocessed and Reused on a Patient? (Y/N)
No
Usage of Device Initial
Patient Sequence Number1
Concomitant Medical Products
and Therapy/Usage Dates
CLOPIDOGREL (PLAVIX); ELIQUIS
Outcome Attributed to Adverse Event Required Intervention;
Patient Age60 YR
Patient SexFemale
Patient Weight190 KG
Patient EthnicityNon Hispanic
Patient RaceBlack Or African American
-
-